Clearmind Medicine Inc Ordinary Shares CMND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Trading Information
- Previous Close Price
- $4.18
- Day Range
- $3.24–4.00
- 52-Week Range
- $3.24–1,272.00
- Bid/Ask
- $1.43 / $4.68
- Shares Outstanding
- 507,404.00
- Market Cap
- $1.75M
- Volume/Avg
- 221 / 55,901
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
Valuation
Metric | CMND |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.09 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CMND |
|---|---|
Quick Ratio | 4.28 |
Current Ratio | 4.31 |
Interest Coverage | −1,041.52 |
Quick Ratio
CMND
Profitability
Metric | CMND |
|---|---|
Return on Assets (Normalized) | −74.89% |
Return on Equity (Normalized) | −194.83% |
Return on Invested Capital (Normalized) | −104.56% |
Return on Assets
CMND
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%R%r!d | LOCK|@L?# | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|^l@?^@^ | LOCK|FDt< | $99B | |||
| Moderna Inc MRNA | LOCK|%@?%LRF | LOCK|@& | $84B | |||
| argenx SE ADR ARGX | LOCK|p!$W#P | LOCK|Y! | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|z<b#>ZP | LOCK|VqD | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Yyj?dtF> | LOCK|q##!? | $31B | |||
| Incyte Corp INCY | LOCK|L$tM@#> | LOCK|l#w | $24B | |||
| BioNTech SE ADR BNTX | LOCK|t&bQ!qs | LOCK|y<q | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|kWc!n?& | LOCK|hj!^ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|JcFX<<! | LOCK|fS | $15B |